AtriCure, Inc. (NASDAQ:ATRC) Shares Acquired by Diversified Trust Co

Diversified Trust Co lifted its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 13.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,731 shares of the medical device company’s stock after acquiring an additional 4,751 shares during the period. Diversified Trust Co owned 0.08% of AtriCure worth $1,114,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Comerica Bank raised its position in shares of AtriCure by 70.5% during the 1st quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock worth $77,000 after acquiring an additional 1,043 shares in the last quarter. Quest Partners LLC increased its position in AtriCure by 38.3% during the second quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock worth $134,000 after buying an additional 1,626 shares during the period. Virtu Financial LLC acquired a new position in AtriCure during the fourth quarter worth approximately $213,000. Mount Yale Investment Advisors LLC increased its position in AtriCure by 32.1% during the second quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company’s stock worth $222,000 after buying an additional 2,368 shares during the period. Finally, ProShare Advisors LLC increased its position in AtriCure by 8.5% during the first quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company’s stock worth $255,000 after buying an additional 659 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Up 0.9 %

AtriCure stock opened at $27.32 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.13 and a quick ratio of 2.93. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.00. The company has a market cap of $1.30 billion, a PE ratio of -34.15 and a beta of 1.44. The stock’s 50 day moving average price is $25.59 and its 200 day moving average price is $24.21.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. The firm had revenue of $116.27 million for the quarter, compared to the consensus estimate of $116.24 million. During the same period in the previous year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 15.2% compared to the same quarter last year. On average, sell-side analysts predict that AtriCure, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on ATRC. BTIG Research cut their price target on AtriCure from $58.00 to $53.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a research report on Saturday, September 14th. Needham & Company LLC cut their price target on AtriCure from $40.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. cut their price target on AtriCure from $34.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Finally, Stifel Nicolaus lowered their target price on AtriCure from $30.00 to $26.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.44.

Insider Activity at AtriCure

In related news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $24.07, for a total value of $84,245.00. Following the sale, the director now directly owns 8,970 shares in the company, valued at $215,907.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.20% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.